AMAG Pharmaceuticals (AMAG) Shares are Down -11.77%

AMAG Pharmaceuticals (AMAG) : During the past 4 weeks, traders have been relatively bearish on AMAG Pharmaceuticals (AMAG), hence the stock is down -5.54% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -11.82% relative to the S&P 500. The 4-week change in the price of the stock is -4.57% and the stock has fallen -11.77% in the past 1 week.

The stock has recorded a 20-day Moving Average of 6.01% and the 50-Day Moving Average is 0.35%. AMAG Pharmaceuticals (NASDAQ:AMAG): stock turned positive on Friday. Though the stock opened at $23.35, the bulls momentum made the stock top out at $24.53 level for the day. The stock recorded a low of $23.13 and closed the trading day at $24.44, in the green by 5.85%. The total traded volume for the day was 967,385. The stock had closed at $23.09 in the previous days trading.


The company Insiders own 2.3% of AMAG Pharmaceuticals shares according to the proxy statements. Also, In a research note released to the investors, Jefferies maintains its rating on AMAG Pharmaceuticals (NASDAQ:AMAG).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Jefferies lowers the new price target from $58 per share to $45 per share. The rating by the firm was issued on August 11, 2016.

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.